

Infliximab

Chemical Properties

CAS No. :	170277-31-3
Formula:	
Molecular Weight:	145.98 kDa
Storage:	Store at low temperature
	-20°C for 1 year
	Actual storage temperature shall be subject to the COA.

Biological Description

Description	Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF- α and prevents TNF- α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.
Targets(IC50)	Antibacterial, TNF
In vitro	<p>METHODS: Human lung cancer cells A549 were pretreated with ML162 (0.1-15 μM) for 4-24 h. TXNRD1 activity was measured with the RX1 activity probe.</p> <p>RESULTS: RX1 signaling was significantly dose-dependently inhibited at ML162 concentrations of 0.5 μM or higher. there was also a fairly rapid onset of concentration-dependent inhibition of cellular TXNRD1 activity by ML162, and a 4 h incubation with 1 μM or higher ML162 treatment was sufficient to inhibit RX1 signaling. ML162 effectively inhibited cellular TXNRD1 activity.[1]</p> <p>METHODS: Melanoma cells A2058 and A375 were pretreated with ferrostatin (10 μM), Z-VAD-FMK (10 μM), or necrosulfonamide (0.5 μM) for 24 h, and cell viability was measured after ML162 (1-16 μM) treatment.</p> <p>RESULTS: ML162 caused cell death in a dose-dependent manner in the A2058 and A375 melanoma cell lines, which could be reversed by ferrostatin-1, a ferritin-specific inhibitor, but not by Z-VAD-FMK, an inhibitor of apoptosis, or necrosulfonamide, an inhibitor of necroptosis. [2]</p>
In vivo	<p>METHODS: To detect anti-tumor activity in vivo, ML162 (40 mg/kg once daily) and anti-PD-1 antibody (200 μg every three days) were intraperitoneally injected into BALB/c mice bearing TS/A tumors once daily for two weeks.</p> <p>RESULTS: The combination of GPX4 inhibitor and anti-PD-1 antibody significantly inhibited tumor growth compared to monotherapy. The combination therapy did not result in additional immune cell infiltration compared to monotherapy, but the combination therapy induced a significant immune response with an increased proportion of PRF1+CD8+ T cells and GZMB+CD8+ T cells. [3]</p>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.0069 mL	0.0343 mL	0.0685 mL
5 mM	0.0014 mL	0.0069 mL	0.0137 mL
10 mM	0.0007 mL	0.0034 mL	0.0069 mL
50 mM	0.0001 mL	0.0007 mL	0.0014 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481